{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:19:17Z","timestamp":1783081157645,"version":"3.54.6"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"am","delay-in-days":404,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.therap.2022.05.001","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T10:52:25Z","timestamp":1651920745000},"page":"693-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic"],"prefix":"10.1016","volume":"77","author":[{"given":"\u00c9milien","family":"Schultz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9o","family":"Mignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy K.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Boaventura Bomfim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2022.05.001_bib0245","article-title":"Covid-19 controversies: the tocilizumab chapter","volume":"372","author":"McCreary","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2022.05.001_bib0250","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.coviro.2021.06.004","article-title":"Progress and pitfalls of a year of drug repurposing screens against COVID-19","volume":"49","author":"Sourimant","year":"2021","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.therap.2022.05.001_bib0255","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1440783321999453","article-title":"Science under Covid-19's magnifying glass: lessons from the first months of the chloroquine debate in the French press","volume":"58","author":"Schultz","year":"2022","journal-title":"J Sociol"},{"key":"10.1016\/j.therap.2022.05.001_bib0260","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/maq.12622","article-title":"Hydroxychloroquine controversies: clinical trials, epistemology, and the democratization of science","volume":"34","author":"Berlivet","year":"2020","journal-title":"Med Anthropol Q"},{"key":"10.1016\/j.therap.2022.05.001_bib0265","first-page":"10","article-title":"Commercial influence and covid-19: greater independence from commercial interests is more important than ever","volume":"369","author":"Moynihan","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2022.05.001_bib0270","series-title":"Vaccine hesitancy: public trust, expertise, and the war on science","first-page":"264","author":"Goldenberg","year":"2021"},{"key":"10.1016\/j.therap.2022.05.001_bib0275","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-publhealth-090419-102240","article-title":"Vaccine hesitancy, acceptance, and anti-vaccination: trends and future prospects for public health","volume":"42","author":"Dub\u00e9","year":"2020","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.therap.2022.05.001_bib0280","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2022.01.008","article-title":"Does the public know when a scientific controversy is over? Public perceptions of hydroxychloroquine in France between April 2020 and June","volume":"77","author":"Schultz","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.05.001_bib0285","series-title":"Between an ethics of care and scientific uncertainty: dilemmas of general practitioners in Marseille. In: The COVID-19 crisis: Social perspectives","first-page":"144","author":"Lutaud","year":"2021"},{"key":"10.1016\/j.therap.2022.05.001_bib0290","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/eurpub\/ckab002","article-title":"The hydroxychloroquine debate: a therapeutic dilemma for general practitioners","volume":"31","author":"Lutaud","year":"2021","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.therap.2022.05.001_bib0295","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40264-020-00965-w","article-title":"The impact of the COVID-19 \u201cInfodemic\u201d on drug-utilization behaviors: implications for pharmacovigilance","volume":"43","author":"Tuccori","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2022.05.001_bib0300","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.therap.2020.05.010","article-title":"Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence","volume":"75","author":"Roustit","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.05.001_bib0305","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.therap.2021.05.010","article-title":"COVID-19 vaccines: a perspective from social pharmacology","volume":"76","author":"Montastruc","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.05.001_bib0310","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008915","article-title":"Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review","volume":"5","author":"Colgan","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.therap.2022.05.001_bib0315","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/hec.3353","article-title":"Preferences for \u00ab\u00a0new\u00a0\u00bb treatments diminish in the face of ambiguity","volume":"26","author":"Harrison","year":"2017","journal-title":"Heal Econ"},{"key":"10.1016\/j.therap.2022.05.001_bib0320","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/mar.21395","article-title":"Older is better: consumers prefer older drugs","volume":"37","author":"Jie","year":"2020","journal-title":"Psychol Mark"},{"key":"10.1016\/j.therap.2022.05.001_bib0325","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jval.2018.12.007","article-title":"Understanding patients\u2019 preferences: a systematic review of psychological instruments used in patients\u2019 preference and decision studies","volume":"22","author":"Russo","year":"2019","journal-title":"Value Heal"},{"key":"10.1016\/j.therap.2022.05.001_bib0330","series-title":"The crisis of expertise","first-page":"208","author":"Eyal","year":"2019"},{"key":"10.1016\/j.therap.2022.05.001_bib0335","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.3390\/ijerph18052611","article-title":"French public familiarity and attitudes toward clinical research during the COVID-19 pandemic","volume":"18","author":"Schultz","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2022.05.001_bib0340","doi-asserted-by":"crossref","first-page":"113414","DOI":"10.1016\/j.socscimed.2020.113414","article-title":"The French public's attitudes to a future COVID-19 vaccine: the politicization of a public health issue","volume":"265","author":"Ward","year":"2020","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.therap.2022.05.001_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijerph17165731","article-title":"Challenges in navigating the health care system: development of an instrument measuring navigation health literacy","volume":"17","author":"Griese","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2022.05.001_bib0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0208091","article-title":"Validity and measurement invariance across sex, age, and education level of the French short versions of the European Health Literacy Survey Questionnaire","volume":"13","author":"Rouquette","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2022.05.001_bib0355","series-title":"Applied logistic regression","first-page":"510","author":"Hosmer","year":"2013"},{"key":"10.1016\/j.therap.2022.05.001_bib0360","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/14461242.2016.1170624","article-title":"Knowledge matters: producing and using knowledge to navigate healthcare systems","volume":"25","author":"Willis","year":"2016","journal-title":"Heal Sociol Rev"},{"key":"10.1016\/j.therap.2022.05.001_bib0365","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/1467-9566.13028","article-title":"A Bourdieusian approach to class-related inequalities: the role of capitals and capital structure in the utilisation of healthcare services in later life","volume":"42","author":"Paccoud","year":"2020","journal-title":"Sociol Heal Illn"},{"key":"10.1016\/j.therap.2022.05.001_bib0370","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0963662504042690","article-title":"Science in society: re-evaluating the deficit model of public attitudes","volume":"13","author":"Sturgis","year":"2004","journal-title":"Public Underst Sci"},{"key":"10.1016\/j.therap.2022.05.001_bib0375","doi-asserted-by":"crossref","unstructured":"Besle S, Sarradon-Eck A. Choisir le risque: l\u2019autonomie du malade en situation d\u2019\u00e9chec th\u00e9rapeutique. Anthropol Sant\u00e9 2019. https:\/\/journals.openedition.org\/anthropologiesante\/4817#quotation. [Accessed 2 May 2022].","DOI":"10.4000\/anthropologiesante.4817"},{"key":"10.1016\/j.therap.2022.05.001_bib0380","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bulcan.2021.04.013","article-title":"Actuality of conflicts of interests in medicine. From financial interests to the run for scientific publication","volume":"108","author":"Maraninchi","year":"2021","journal-title":"Bull Cancer"},{"key":"10.1016\/j.therap.2022.05.001_bib0385","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.drudis.2020.08.001","article-title":"Global clinical trial mobilization for COVID-19: higher, faster, stronger","volume":"25","author":"Beall","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.therap.2022.05.001_bib0390","series-title":"Conflict of interest and medicine. Knowledge, practice and mobilizations","first-page":"270","author":"Hauray","year":"2021"},{"key":"10.1016\/j.therap.2022.05.001_bib0395","series-title":"Ghost-managed medicine: Big pharma's invisible hands","first-page":"231","author":"Sismondo","year":"2018"},{"key":"10.1016\/j.therap.2022.05.001_bib0400","series-title":"Unhealthy Pharmaceutical Regulation","first-page":"321","author":"Davis","year":"2013"},{"key":"10.1016\/j.therap.2022.05.001_bib0405","series-title":"Cancer on trial. Oncology as a new style of practice","first-page":"476","author":"Keating","year":"2011"},{"key":"10.1016\/j.therap.2022.05.001_bib0410","first-page":"171","article-title":"Quelle place pour les associations de malades dans le processus d\u2019innovation m\u00e9dicamenteuse?","volume":"3\u20134","author":"Dalgalarrondo","year":"2007","journal-title":"Rev Fr Aff Soc"},{"key":"10.1016\/j.therap.2022.05.001_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6963-9-150","article-title":"Factors influencing prescribing behaviour of physicians in Greece and Cyprus: results from a questionnaire based survey","volume":"9","author":"Theodorou","year":"2009","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.therap.2022.05.001_bib0420","first-page":"1","article-title":"New drugs: where did we go wrong and what can we do better?","volume":"366","author":"Wieseler","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2022.05.001_bib0425","article-title":"FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway","volume":"374","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2022.05.001_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0175643","article-title":"Perceived conflict of interest in health science Partnerships","volume":"12","author":"Besley","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2022.05.001_bib0435","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.socscimed.2014.12.007","article-title":"Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?","volume":"131","author":"Davis","year":"2015","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.therap.2022.05.001_bib0440","doi-asserted-by":"crossref","first-page":"113042","DOI":"10.1016\/j.socscimed.2020.113042","article-title":"Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US","volume":"258","author":"Salas-Vega","year":"2020","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.therap.2022.05.001_bib0445","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3917\/crpsy.005.0122","article-title":"Th\u00e9rapies cellulaires et g\u00e9niques: la gu\u00e9rison \u00e0 l\u2019horizon?","volume":"5","author":"Chabannon","year":"2021","journal-title":"Cancer(s) et psy(s)"},{"key":"10.1016\/j.therap.2022.05.001_bib0450","article-title":"Determinants of radical drug innovation: a systematic literature review","author":"Stiller","year":"2021","journal-title":"Manag Rev Q"},{"key":"10.1016\/j.therap.2022.05.001_bib0455","doi-asserted-by":"crossref","first-page":"112621","DOI":"10.1016\/j.socscimed.2019.112621","article-title":"Tracking biomedicalization in the media: Public discourses on health and medicine in the UK and Italy, 1984-2017","volume":"243","author":"Neresini","year":"2019","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.therap.2022.05.001_bib0460","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/09537320600777002","article-title":"The sociology of expectations in science and technology","volume":"18","author":"Borup","year":"2006","journal-title":"Technol Anal Strateg Manag"},{"key":"10.1016\/j.therap.2022.05.001_bib0465","series-title":"Transparency, power, and influence in the pharmaceutical industry: policy gain or confidence game?","first-page":"304","author":"Fierlbeck","year":"2021"},{"key":"10.1016\/j.therap.2022.05.001_bib0470","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/0963662520924259","article-title":"Science-related populism: conceptualizing populist demands toward science","volume":"29","author":"Mede","year":"2020","journal-title":"Public Underst Sci"},{"key":"10.1016\/j.therap.2022.05.001_bib0475","unstructured":"LEEM. Observatoire soci\u00e9tal du m\u00e9dicament. 2019. https:\/\/www.leem.org\/publication\/observatoire-societal-du-medicament-2019-ipsos-pour-le-leem. [Accessed 2 May 2022]."},{"issue":"2","key":"10.1016\/j.therap.2022.05.001_bib0480","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3917\/mouv.098.0067","article-title":"\u00ab\u00a0Mediator n\u2019est pas une exception, mais le r\u00e9v\u00e9lateur de probl\u00e8mes structurels dans le monde du m\u00e9dicament\u00a0\u00bb","volume":"98","author":"Gaudilli\u00e8re","year":"2019","journal-title":"Mouvements"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:31Z","timestamp":1758567331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595722000932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0040595722000932"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.05.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}